NCT06760260 2025-01-07
Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Recruiting
Clinical Trials
11 trialsNCT06702098 2024-11-22
iNK-r/r AML
Guangzhou Ruixin Biotechnological Co., LTD
Phase EARLY_PHASE1 Not yet recruiting
NCT06541405 2024-08-07
Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT06541444 2024-08-07
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT03224819 2023-09-01
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Amgen
Phase EARLY_PHASE1 Terminated
NCT05722171 2023-02-10
Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05432401 2022-06-27
TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT01843634 2021-11-10
Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Jazz Pharmaceuticals
Phase EARLY_PHASE1 Completed
NCT03795779 2021-05-19
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT04209712 2020-07-29
Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Phase EARLY_PHASE1 Unknown
NCT04156256 2019-11-12
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown